spironolactone ceva
ceva santé animale - spironolakton - diuretiki - psi - za uporabo v kombinaciji s standardno terapijo (vključno z diuretiki podporo, kadar je to potrebno) za zdravljenje kongestivnega srčnega popuščanja zaradi valvular regurgitacija v psi.
vydura
pfizer europe ma eeig - rimegepant - bolezni migrene - antimigraine preparations, calcitonin gene-related peptide (cgrp) antagonists - vydura is indicated for theacute treatment of migraine with or without aura in adults;preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.
gemcitabin ''ebewe'' 1000 mg prašek za raztopino za infundiranje
ebewe pharma - gemcitabin - prašek za raztopino za infundiranje - gemcitabin 1000 mg / 1 viala - gemcitabin
gemcitabin ''ebewe'' 200 mg prašek za raztopino za infundiranje
ebewe pharma - gemcitabin - prašek za raztopino za infundiranje - gemcitabin 200 mg / 1 viala - gemcitabin
gemcitabin ''ebewe'' 200 mg prašek za raztopino za infundiranje
ebewe pharma - gemcitabin - prašek za raztopino za infundiranje - gemcitabin 200 mg / 1 viala - gemcitabin
clozalux 100 mg tablete
tableta - klozapin
gemcitabin ''ebewe'' 1000 mg prašek za raztopino za infundiranje
ebewe pharma - gemcitabin - prašek za raztopino za infundiranje - gemcitabin 1000 mg / 1 viala - gemcitabin
raplixa
mallinckrodt pharmaceuticals ireland limited - humani fibrinogen, humani trombin - hemostaz, kirurški - antihemoragije - podporno zdravljenje, kjer standardne kirurške tehnike ne zadoščajo za izboljšanje haemostasis. raplixa je treba uporabljati v kombinaciji z odobrenim želatina goba. raplixa je navedeno v odrasli nad 18 let.
dimethyl fumarate neuraxpharm
laboratorios lesvi s.l. - dimetil fumarat - multiplo sklerozo, recidivno-nakazila - imunosupresivi - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostatične neoplazme - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.